FDA Urged to Keep Distinctions Between Biologics and Copies
By Mari Serebrov
Washington Editor
Washington Editor
Tuesday, June 18, 2013
Biologics are innovative drugs, biosimilars are copies, and never the twain shall meet. That's the underlying message brand drugmakers sent to the FDA as they urged it to maintain the distinctions between the 351(a) and 351(k) approval paths.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
Our address has changed:
BioWorld | 115 Perimeter Center Place
Suite: 1100 | Atlanta, Georgia 30346, USA
Suite: 1100 | Atlanta, Georgia 30346, USA
For Sales Inquiries,
http://ip-science.interest.thomsonreuters.com/Bioworld_Sales_Inquiry
NORTH AMERICA
Tel: +1-855-260-5607
Outside of the US
Tel. +44-203-684-1797
http://ip-science.interest.thomsonreuters.com/Bioworld_Sales_Inquiry
NORTH AMERICA
Tel: +1-855-260-5607
Outside of the US
Tel. +44-203-684-1797
Part of Thomson Reuters
Note: our contact information has changed
Customer Service:
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
http://ip-science.thomsonreuters.com/support/#open_a_support_case
Hours: Monday - Friday, 8:00am - 6:00 pm EST
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
http://ip-science.thomsonreuters.com/support/#open_a_support_case
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2015 Thomson Reuters. Reproduction, reposting content is strictly prohibited.
Free Ezine
Sign up for Highlights FREE e-mail newsletter